Literature DB >> 20429759

Whole-body MRI in follow-up of patients with renal cell carcinoma.

Ivan Platzek1, Stefan Zastrow, Pierre-Emanuel Deppe, Marc-Oliver Grimm, Manfred Wirth, Michael Laniado, Christian Stroszczynski.   

Abstract

BACKGROUND: Recent technological advances have made whole-body MRI feasible within a reasonable time-frame. The clinical utility of whole-body MRI in patients with renal cell carcinoma has not been evaluated yet.
PURPOSE: To compare the diagnostic accuracy of whole-body MRI and computed tomography (CT) in follow-up of patients with renal cell carcinoma.
MATERIAL AND METHODS: In 28 patients with primary renal cell carcinoma a multislice CT scan of the thorax, abdomen, and pelvis, and a whole-body MRI were carried out as part of the postoperative follow-up. A combination of subsequent imaging studies and histology served as standard of reference.
RESULTS: MRI demonstrated a significantly better diagnostic accuracy regarding musculoskeletal metastases compared with CT (97.7% vs 82%, P<0.001). In contrast, CT was superior in the detection of pulmonary metastases (88.5% vs 71.9%, P<0.001). Both methods had similar diagnostic performance regarding lymph node metastases (CT, accuracy 82.4%; MRI, accuracy 83.4%, P=0.25). The concordance of both modalities regarding N and M stage was excellent (Cohen's kappa 1.00). In two patients cerebral metastases were revealed by MRI, which led to a change in therapy.
CONCLUSION: At this stage, whole-body MRI cannot be considered an adequate replacement for CT in the follow-up of patients with renal cell carcinoma. Further significant improvement of lung MR protocols is necessary, as CT's sensitivity for pulmonary nodules is clearly superior. In contrast, the main advantage of whole-body MRI is its high diagnostic accuracy for musculoskeletal metastases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20429759     DOI: 10.3109/02841851003724846

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  8 in total

1.  Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Authors:  Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2018-05-31       Impact factor: 1.862

Review 2.  Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

Authors:  Luís León; Roberto García-Figueiras; Roberto García-Figueras; Cristina Suárez; Antonia Arjonilla; Javier Puente; Blanca Vargas; Maria José Méndez Vidal; Carmen Sebastiá
Journal:  Target Oncol       Date:  2013-12-12       Impact factor: 4.493

Review 3.  Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma.

Authors:  Alberto Diaz de Leon; Ali Pirasteh; Daniel N Costa; Payal Kapur; Hans Hammers; James Brugarolas; Ivan Pedrosa
Journal:  Radiographics       Date:  2019-06-14       Impact factor: 5.333

4.  Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?

Authors:  Giuseppe Petralia; Anwar Padhani; Paul Summers; Sarah Alessi; Sara Raimondi; Alessandro Testori; Massimo Bellomi
Journal:  Eur Radiol       Date:  2013-07-25       Impact factor: 5.315

Review 5.  Magnetic resonance imaging for lung cancer screen.

Authors:  Yi-Xiang J Wang; Gladys G Lo; Jing Yuan; Peder E Z Larson; Xiaoliang Zhang
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

6.  Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.

Authors:  Pierpaolo Alongi; Maria Picchio; Fabio Zattoni; Marianna Spallino; Luigi Gianolli; Giorgio Saladini; Laura Evangelista
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-14       Impact factor: 9.236

Review 7.  [Focal therapy for small renal masses : Observation, ablation or surgery].

Authors:  J J Wendler; B Friebe; D Baumunk; A Blana; T Franiel; R Ganzer; B Hadaschik; T Henkel; K U Köhrmann; J Köllermann; T Kuru; S Machtens; A Roosen; G Salomon; H P Schlemmer; L Sentker; U Witzsch; U B Liehr; J Ricke; M Schostak
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

8.  Available active surveillance follow-up protocols for small renal mass: a systematic review.

Authors:  Giacomo Rebez; Nicola Pavan; M Carmen Mir
Journal:  World J Urol       Date:  2021-01-16       Impact factor: 4.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.